{"id":51562,"date":"2022-12-05T15:02:22","date_gmt":"2022-12-05T14:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/"},"modified":"2022-12-05T15:02:22","modified_gmt":"2022-12-05T14:02:22","slug":"immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/","title":{"rendered":"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia"},"content":{"rendered":"
\n

\n– Proven excellent therapeutic effect with 60% objective response rate and 100% complete remission in patients with NK\/T cell lymphoma<\/b>\n<\/p>\n

<\/a><\/p>\n

SEONGNAM, South Korea–(BUSINESS WIRE)–#ENKTL<\/a>—ImmuneOncia<\/a> (CEO Heung Tae Kim) announced the results of its Phase 2 NK\/T-cell lymphoma clinical trial of IMC-001, a PD-L1 monoclonal antibody, at the Asian Congress of the European Society for Medical Oncology (ESMO Asia 2022)<\/a> held in Singapore on December 4th, 2022.\n<\/p>\n

\nThe clinical data demonstrated that 6 out of 10 evaluable patients (60%) achieved an objective response, all of whom showed a complete remission (CR). Additionally, the administration has been continued in 4 of these 6 patients for over a year, which also indicates its outstanding safety (in terms of the long-term toxicity) and durable response.\n<\/p>\n

\nThanks to these achievements, the results of IMC-001 were selected for Mini Oral Session at ESMO Asia this year.\n<\/p>\n

\nProfessor Won Seog Kim of Samsung Medical Center, a presenter and Principal Investigator of IMC-001, commented, \u201cThe complete remission and response rate of 60% of IMC-001 significantly outperform currently available drugs for the treatment, and very rare adverse events of grade 3 or higher also eliminate concerns over the side effects, making it the best-in-class among PD-(L)1 drugs. These results are expected to satisfy the criteria for approval and lead to globalization of an immune checkpoint inhibitor developed by a Korean biotech.\u201d\n<\/p>\n

\nNK\/T cell lymphoma is a rare cancer that occurs mostly in Asian countries such as China and Korea, and often treated with radiation and chemotherapy. NK\/T cell lymphoma has a high recurrence rate of 75% within 2 years. Due to the absence of standard-of-care treatment for relapsed\/refractory, it has high unmet needs. So far, no single immuno-oncology drug has obtained approval in this indication across the globe.\n<\/p>\n

\nIMC-001 is a PD-L1 antibody, an immune checkpoint inhibitor that serves as the basis of the current immuno-oncology market. This antibody activates the anticancer functions of T cells by strongly inhibiting the binding between PD-1 expressed on T cells and PD-L1 expressed on the surface of cancer cells. Moreover, it can mediate ADCC (antibody-dependent cellular cytotoxicity) against tumor cells, as it maintains the Fc effector function using human IgG1.\n<\/p>\n

\nHeung Tae Kim, CEO of ImmuneOncia said, \u201cThis achievement sets a new standard for the second-line treatment of NK\/T-cell lymphoma, which has high unmet needs. This will be a momentum to secure more partnering opportunities in regions with a high incidence of NK\/T-cell lymphoma, like China. ImmuneOncia is also preparing additional clinical trials to expand its indications in solid cancer.\u201d\n<\/p>\n

\nImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation<\/a> of Korea and a Nasdaq-listed Sorrento Therapeutics<\/a> in the US. In addition to IMC-001, ImmuneOncia has a wide range of new products in the pipeline, such as IMC-002, a CD47 antibody, and IMC-201, a bispecific antibody.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nImmuneOncia Therapeutics, Inc.\n<\/p>\n

\nJiyoung Chu
\n
+82 31-604-8110
\n
PR@immuneoncia.com<\/a>\n<\/p>\n

\nJeongsik Choi
\n
+82 31-604-8133
\n
BD@immuneoncia.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Proven excellent therapeutic effect with 60% objective response rate and 100% complete remission in patients with NK\/T cell lymphoma SEONGNAM, South Korea–(BUSINESS WIRE)–#ENKTL—ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 2 NK\/T-cell lymphoma clinical trial of IMC-001, a PD-L1 monoclonal antibody, at the Asian Congress of the European Society for Medical … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51562","6":"format-standard","7":"category-industry"},"yoast_head":"\nImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Proven excellent therapeutic effect with 60% objective response rate and 100% complete remission in patients with NK\/T cell lymphoma SEONGNAM, South Korea–(BUSINESS WIRE)–#ENKTL—ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 2 NK\/T-cell lymphoma clinical trial of IMC-001, a PD-L1 monoclonal antibody, at the Asian Congress of the European Society for Medical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-05T14:02:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221205005006\/en\/1649297\/21\/IO_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia\",\"datePublished\":\"2022-12-05T14:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/\"},\"wordCount\":496,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005006\\\/en\\\/1649297\\\/21\\\/IO_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/\",\"name\":\"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005006\\\/en\\\/1649297\\\/21\\\/IO_logo.jpg\",\"datePublished\":\"2022-12-05T14:02:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005006\\\/en\\\/1649297\\\/21\\\/IO_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221205005006\\\/en\\\/1649297\\\/21\\\/IO_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/","og_locale":"en_US","og_type":"article","og_title":"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia - Pharma Trend","og_description":"– Proven excellent therapeutic effect with 60% objective response rate and 100% complete remission in patients with NK\/T cell lymphoma SEONGNAM, South Korea–(BUSINESS WIRE)–#ENKTL—ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 2 NK\/T-cell lymphoma clinical trial of IMC-001, a PD-L1 monoclonal antibody, at the Asian Congress of the European Society for Medical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-05T14:02:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221205005006\/en\/1649297\/21\/IO_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia","datePublished":"2022-12-05T14:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/"},"wordCount":496,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221205005006\/en\/1649297\/21\/IO_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/","url":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/","name":"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221205005006\/en\/1649297\/21\/IO_logo.jpg","datePublished":"2022-12-05T14:02:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221205005006\/en\/1649297\/21\/IO_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221205005006\/en\/1649297\/21\/IO_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51562"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51562\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}